SCHEMBL17273271

SCHEMBL17273271

Cc1c(Cl)cc(C(C)C)c(O)c1[Se]c1c(C)c(Cl)cc(C(C)C)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 0.48
GABRB1 P18505 5/20 0.48
LMNA P02545 3/20 0.47
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
GABRB2 P47870 3/20 0.39
GSR P00390 1/20 0.34
GAA P10253 3/20 0.33
SLC6A2 P23975 2/20 0.33
HTR2B P41595 2/20 0.33
HIF1A Q16665 2/20 0.33
FAAH O00519 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
GABRG2 P18507 1/20 0.33
PTGS1 P23219 1/20 0.33
HTR2C P28335 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283809 0.76 GABRA1 (0.50) GABRA1GABRB1LMNACA1CA2
SCHEMBL15698348 0.75 LMNA (0.52) GABRA1GABRB1LMNACA1CA2
SCHEMBL4613445 0.75 GABRA1 (0.54) GABRA1GABRB1LMNACA1CA2
SCHEMBL29810169 0.74 GABRA1 (0.48) GABRA1GABRB1LMNACA1CA2
Biclotymol SCHEMBL31496050 0.74 HIF1A (0.54) GABRA1GABRB1LMNACA1CA2
SCHEMBL17160048 0.74 GABRA1 (0.48) GABRA1GABRB1LMNACA1CA2
SCHEMBL572969 0.74 GABRA1 (0.48) GABRA1GABRB1LMNACA1CA2
Biclotymol SCHEMBL70634 0.74 HIF1A (0.54) GABRA1GABRB1LMNACA1CA2
SCHEMBL2787398 0.71 FABP3 (0.46) GABRA1GABRB1LMNACA1CA2
SCHEMBL5642327 0.71 GABRA1 (0.46) GABRA1GABRB1LMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150336885-A1 PROCESS FOR PREPARING 2,2'-SELENOBIARYL ETHERS OR 4,4'-SELENOBIARYL ETHERS USING SELENIUM DIOXIDE EVONIK DEGUSSA GMBH (DE) 2015-11-26 US claimed
EP-2949646-A1 METHOD FOR THE PREPARATION OF 2,2'SELENOBIARYLETHERS OR 4,4'SELENOBIARYLETHERS USING SELENIUM DIOXIDE Evonik Degussa GmbH (DE) 2015-12-02 EP disclosed
US-20150336885-A1 PROCESS FOR PREPARING 2,2'-SELENOBIARYL ETHERS OR 4,4'-SELENOBIARYL ETHERS USING SELENIUM DIOXIDE EVONIK DEGUSSA GMBH (DE) 2015-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336885-A1 PROCESS FOR PREPARING 2,2'-SELENOBIARYL ETHERS OR 4,4'-SELENOBIARYL ETHERS USING SELENIUM DIOXIDE SELENOI, SCLY, SPIN4 GABRA1 3326/4885GABRB1 2546/4885LMNA 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.